2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2140 Efficacy and safety of sonrotoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up from a multicenter, open-label, phase 2 study

Shuhua Yi, DO, Keshu Zhou, PhD2, Ning Liu3, Wei Sang, PhD4, Rui Huang5, Yi Wang Sr, PhD6, Chenghui Zhang7, Fudao Wu8, Ying Li9, Mei Sun10, Jian-Qing Mi11, Kaiyang Ding, MD12, Sujun Gao13, Qiaohua Zhang14, Haiying Hua, MD15, Xiaoxia Chu16, Jian Cheng17, Aikebaier Abudureyimu18, Lanyun Zhou19, Cheryl Chow20, Xiao Lin21, Shaojun Pan22, Zhiyu Liang23, Remus Vezan, MD, PhD24, Lu-Gui Qiu, PhD25
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
2 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
3 Jining No. 1 People's Hospital, Shandong, China
4 The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
5 Zhujiang Hospital of Southern Medical University, Guangdong, China
6 Shaanxi Provincial People's Hospital, Xi'an, China
7 Nanyang Central Hospital, Henan, China
8 Dazhou Central Hospital, Dazhou, China
9 Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
10 Northern Jiangsu People's Hospital, Yangzhou, China
11 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
12 Anhui Provincial Cancer Hospital, Hefei, China
13 The First Hospital of Jilin University, Changchun, China
14 Shanxi Bethune Hospital, Shanxi, China
15 Affiliated Hospital of Jiangnan University-South Campus, Jiangsu, China
16 Yantai Yuhuangding Hospital, Yantai, China
17 Zhongda Hospital Affiliated to Southeast University, Jiangsu, China
18 The First People's Hospital of Kashgar, Kashgar, China
19 BeOne Medicines, Ltd, Shanghai, China
20 BeOne Medicines, Ltd, San Carlos, CA, United States
21 BeOne Medicines, Ltd, Shanghai, China
22 BeOne Medicines, Ltd, Shanghai, China
23 BeOne Medicines, Ltd, Shanghai, China
24 BeOne Medicines, Ltd, San Carlos, CA, United States
25 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China

Introduction: B-cell lymphoma 2 (BCL2) inhibition is an established treatment strategy for CLL/SLL. Sonrotoclax is a next-generation BCL2 inhibitor designed to have high selectivity and pharmacologic potency, and an optimized pharmacokinetic profile characterized by a shorter half-life and minimal drug accumulation. These properties may enable deeper target inhibition while mitigating toxicity. In China, sonrotoclax is approved for adults with CLL/SLL who have had ≥1 prior systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor. In the primary analysis of a single-arm, multicenter, phase 2 study in patients with R/R CLL/SLL (NCT05479994), sonrotoclax demonstrated a favorable safety profile and induced high response rates, including deep responses and undetectable minimal residual disease (uMRD4; sensitivity, 10−4) (Yi et al., ASH 2025). Here, we present updated efficacy and safety results.

Methods: Eligible patients had a confirmed diagnosis of R/R CLL/SLL, received prior chemoimmunotherapy (unless ineligible) and BTK inhibitor therapy, and had no prior BCL2 inhibitor. Patients received sonrotoclax 320 mg once daily following a 4-week twice-weekly or an 8-week weekly dose ramp-up schedule and continued treatment until progressive disease (PD) or unacceptable toxicity. The primary endpoint was independent review committee (IRC)–assessed overall response rate (ORR) per iwCLL 2018 criteria (CLL) or 2014 Lugano criteria (SLL). Secondary endpoints included duration of response (DOR), progression-free survival (PFS), time to response (TTR), overall survival (OS), and safety. Exploratory endpoints included the rate of uMRD4.

Results: One hundred patients with R/R CLL/SLL were enrolled. At baseline, 62.8% (54/86) had unmutated IGHV, 38.1% (37/97) had del(17p)/TP53 mutations, 25.5% (25/98) had a BTK mutation, and 50.0% (50/100) were aged ≥65 yrs. As of May 7, 2026, the median study follow-up was 28.9 months (range, 0.2-42.4). Fifty-two patients (52.0%) continue receiving treatment. The most common reason for treatment discontinuation was PD (32.0%).    

The IRC-assessed ORR was 77.0%, with the complete response rate increasing to 29.0% from the previous report (25.0%). IRC-assessed ORR was 75.9% (41/54) in patients with unmutated IGHV, 70.3% (26/37) in those with del(17p)/TP53 mutations, 72.0% (18/25) in those with BTK mutations, and 78.0% (39/50) in those aged ≥65 yrs. Median TTR was 3.7 months (range, 1.3-11.1). The best uMRD4 rate in peripheral blood (PB) was 53% (53/100) in efficacy-evaluable patients and 77.9% (53/68) in MRD-evaluable patients. Median time from first sonrotoclax dose to PB uMRD4 was 6.4 months (range, 3-16). Patients who achieved PB uMRD4 at C12D1 were less likely to experience PD or death than those with detectable MRD4 (HR, 0.10; 95% CI, 0.02-0.41). Median PFS, DOR, and OS were not reached. The 2-year IRC-assessed PFS rate was 60.7% (95% CI, 49.7%-69.9%). The 2-year OS rate was 76.3% (95% CI, 66.2%-83.8%).

Median duration of sonrotoclax exposure was 21.9 months (range, 0.0-42.4). Most common all-grade/grade ≥3 treatment-emergent adverse events (TEAEs) were hematologic: neutropenia (60.0%/33.0%), thrombocytopenia (53.0%/13.0%), leukopenia (39.0%/12.0%), and anemia (39.0%/5.0%). Serious TEAEs occurred in 46.0% of patients. No additional TEAEs leading to dose reduction or treatment discontinuation have been observed since the primary analysis. No new grade 5 TEAEs were reported.

Conclusions: Sonrotoclax monotherapy demonstrates significant clinical activity in patients with heavily pretreated R/R CLL/SLL with a high rate of uMRD and durable responses. The sonrotoclax toxicity profile remains favorable with extended follow-up. These data add to the growing evidence that sonrotoclax can induce deep responses while maintaining a favorable safety profile across hematologic malignancies.

Shuhua Yi, DO: No relevant conflicts of interest to declare.